Last reviewed · How we verify

Naproxen Sodium Codeine

Istanbul Medeniyet University · FDA-approved active Small molecule

Naproxen sodium inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain, while codeine acts as an opioid agonist to provide additional analgesic and antitussive effects.

Naproxen sodium inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain, while codeine acts as an opioid agonist to enhance analgesia through central nervous system depression. Used for Moderate pain relief, Pain associated with inflammation.

At a glance

Generic nameNaproxen Sodium Codeine
Also known asApranax Plus
SponsorIstanbul Medeniyet University
Drug classNSAID + opioid combination analgesic
TargetCOX-1/COX-2 enzymes; mu opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever. Codeine is an opioid analgesic and antitussive that binds to mu opioid receptors in the central nervous system. The combination provides synergistic pain relief for moderate pain conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: